257 related articles for article (PubMed ID: 35788962)
21. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
[TBL] [Abstract][Full Text] [Related]
22. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
Lee JH; Shewale AR; Barthold D; Devine B
Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.
Schwedt TJ; Alam A; Reed ML; Fanning KM; Munjal S; Buse DC; Dodick DW; Lipton RB
J Headache Pain; 2018 May; 19(1):38. PubMed ID: 29797100
[TBL] [Abstract][Full Text] [Related]
24. Effects of switching acute treatment on disability in migraine patients using triptans.
Serrano D; Buse DC; Kori SH; Papapetropoulos S; Cunanan CM; Manack AN; Reed ML; Lipton RB
Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
[TBL] [Abstract][Full Text] [Related]
25. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study.
Lipton RB; Munjal S; Buse DC; Bennett A; Fanning KM; Burstein R; Reed ML
Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893
[TBL] [Abstract][Full Text] [Related]
26. Triptan persistency among newly initiated users in a pharmacy claims database.
Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
[TBL] [Abstract][Full Text] [Related]
27. Acute treatment patterns in patients with migraine newly initiating a triptan.
Lipton RB; Marcus SC; Shewale AR; Dodick DW; Viswanathan HN; Doshi JA
Cephalalgia; 2020 Apr; 40(5):437-447. PubMed ID: 32138526
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions.
Parkinson B; Gumbie M; Cutler H; Gauld N; Mumford V; Haywood P
Value Health; 2019 Mar; 22(3):293-302. PubMed ID: 30832967
[TBL] [Abstract][Full Text] [Related]
29. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness.
Ceballos Hernansanz MA; Sanchez Roy R; Cano Orgaz A; López-Gil A;
Clin Ther; 2003 Jul; 25(7):2053-69. PubMed ID: 12946550
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
Blumenfeld A; Gennings C; Cady R
Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151
[TBL] [Abstract][Full Text] [Related]
31. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
[TBL] [Abstract][Full Text] [Related]
32. Relation of Testosterone Normalization to Mortality and Myocardial Infarction in Men With Previous Myocardial Infarction.
Oni OA; Dehkordi SHH; Jazayeri MA; Sharma R; Sharma M; Masoomi R; Sharma R; Gupta K; Barua RS
Am J Cardiol; 2019 Oct; 124(8):1171-1178. PubMed ID: 31409450
[TBL] [Abstract][Full Text] [Related]
33. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency.
Cheetham TC; An J; Jacobsen SJ; Niu F; Sidney S; Quesenberry CP; VanDenEeden SK
JAMA Intern Med; 2017 Apr; 177(4):491-499. PubMed ID: 28241244
[TBL] [Abstract][Full Text] [Related]
34. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
Roumie CL; Choma NN; Kaltenbach L; Mitchel EF; Arbogast PG; Griffin MR
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1053-63. PubMed ID: 19637402
[TBL] [Abstract][Full Text] [Related]
35. Triptans for Acute Migraine Headache: Current Experience With Triptan Use and Prescription Habits in a Tertiary Care Headache Outpatient Clinic: An Observational Study.
Fischer M; Frank F; Wille G; Klien S; Lackner P; Broessner G
Headache; 2016 Jun; 56(6):952-60. PubMed ID: 27091593
[TBL] [Abstract][Full Text] [Related]
36. Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data.
Dodick DW; Shewale AS; Lipton RB; Baum SJ; Marcus SC; Silberstein SD; Pavlovic JM; Bennett NL; Young WB; Viswanathan HN; Doshi JA; Weintraub H
J Prim Care Community Health; 2020; 11():2150132720963680. PubMed ID: 33095099
[TBL] [Abstract][Full Text] [Related]
37. Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination.
Cady RK; Banks J; Jones BA; Campbell J
Curr Med Res Opin; 2009 Nov; 25(11):2711-21. PubMed ID: 19778164
[TBL] [Abstract][Full Text] [Related]
38. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.
Tepper S; Allen C; Sanders D; Greene A; Boccuzzi S
Headache; 2003 Jan; 43(1):44-8. PubMed ID: 12864757
[TBL] [Abstract][Full Text] [Related]
39. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
Perearnau P; Vuillemet F; Schick J; Weill G
Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
